Associated tags: Melanocyte, Patient, Pascal (microarchitecture), Melanoma, Cancer, TCR, Infection, Pharmaceutical industry, Neoplasm, ImmTAC, Immunocore
Locations: CANADA, UNITED STATES, EUROPEAN UNION, AUSTRALIA, UNITED KINGDOM
Retrieved on:
Wednesday, February 28, 2024
Research,
HLA,
Nivolumab,
Sale,
Skin,
PRISM,
PR,
SME,
Commercial,
PIWIL1,
Neoplasm,
Research and development,
CTA,
Melanoma,
BMY,
HBV,
Progression-free survival,
Treatment,
GMP,
Cancer,
Bristol Myers Squibb,
Convertible,
APC,
Security (finance),
Congress,
Circulating tumor DNA,
DNA,
Immune system,
Lung cancer,
Total,
ESMO,
Conference,
Safety,
Ovary,
RECIST,
Infection,
Oncology,
IND,
Mum,
Conference call,
PFS,
Note,
Annual report,
Pro forma,
PRAME,
Event,
Patient,
TCR,
HIV,
Pharmaceutical industry Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
Key Points:
- Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
- The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
- Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
- Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.
Conference,
ESMO,
APC,
PRAME,
Treatment,
Lung cancer,
Immune system,
IND,
TCR,
HBV,
CMC,
HLA,
Melanoma,
Nivolumab,
Research,
PIWIL1,
Cancer,
Standard of care,
ImmTAC,
Neoplasm,
HIV,
Ovary,
PST,
Webcast,
Patient,
Infection,
Endometrium,
CTA,
Skin,
Pharmaceutical industry The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
Key Points:
- The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
- The Company has updated its corporate presentation to reflect these business and strategic updates.
- Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
- The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.
Retrieved on:
Thursday, August 10, 2023
& ROCKVILLE, Md., US, 10 August 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune diseases, today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.
Key Points:
- & ROCKVILLE, Md., US, 10 August 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune diseases, today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.
- The Proposed Rule is expected to be finalized during the fourth quarter of 2023 with an effective date of January 1, 2024.
- In the second quarter, Sanofi informed Immunocore that they will not be progressing their evaluation of SAR444245 in combination with KIMMTRAK.
- Immunocore will host a conference call today, August 10, 2023 at 8:00 A.M. EDT/ 1:00 PM BST, to discuss the second quarter financial results and provide a business update.
AACR,
RECIST,
OS,
Cancer,
BRAF,
Uveal melanoma,
Infection,
TCR,
Immunocore,
Translational medicine,
Patient,
Ipilimumab,
Neoplasm,
Society,
American Society of Clinical Oncology,
Pharmaceutical industry,
Medical imaging “We have shown that KIMMTRAK can deliver significant OS benefit to patients with metastatic uveal melanoma, regardless of best RECIST response.
Key Points:
- “We have shown that KIMMTRAK can deliver significant OS benefit to patients with metastatic uveal melanoma, regardless of best RECIST response.
- We have now validated ctDNA reduction as an early surrogate for OS in two separate clinical trials,” said Koustubh Ranade, Vice President of Translational Medicine at Immunocore.
- Patients will be randomized to one of three arms including tebentafusp, as monotherapy or in combination with an anti-PD1, and a control arm.
- Title: A Phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced, non-uveal melanoma
Gastrointestinal cancer,
PRAME,
Patient,
Ipilimumab,
Commercial,
IMC,
Uveal melanoma,
Infection,
Research,
MAD,
Conference,
Book,
Safety,
Abstract,
DNA,
AACR,
HLA,
Cancer,
Record,
BRAF,
Medicine,
Immunotherapy,
TCR,
CROI,
James A. Schlipmann Melanoma Cancer Foundation,
PIWIL1,
Neoplasm,
ImmTAC,
Arm,
HIV,
OS,
CTA,
Fungal infection,
Mum,
Sale,
ASCO,
CTAS,
American Society of Clinical Oncology,
Melanoma,
Annual general meeting,
IND Queens Boulevard Line,
Viral load,
Society,
Pharmaceutical industry,
Cryptocurrency,
Communications satellite,
Immunocore,
IL6 During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
Key Points:
- During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
- In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK.
- The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year.
- The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND / CTA in the fourth quarter of 2023.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
Key Points:
- (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
- & ROCKVILLE, Md., US, 14 March 2023) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, will present four posters at the American Association for Cancer Research Annual Meeting 2023 commencing on 14 April 2023.
IND,
PRAME,
PIWIL1,
NSCLC,
ImmTAC,
Circulating tumor DNA,
HBV,
Neoplasm,
GI,
RECIST,
Immunotherapy,
Autoimmunity,
HIV,
DNA,
Pancreatic cancer,
Infection,
Conference,
ESMO,
Webcast,
TCR,
Patient,
CD3,
Single,
Cancer,
HLE,
Endometrial cancer,
HLA-A24,
Pharmaceutical industry,
Vaccine,
Video game,
Fine chemical,
Q4,
IMC,
Immunocore,
EU In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
Key Points:
- In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
- The IMC-F106C-101 trial is adaptive and enables combinations with standards-of-care including checkpoint inhibitors, chemotherapy, and tebentafusp.
- The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023.
- The Company plans to report data from the Single Ascending Dose portion of the Phase 1 HIV trial in 2023.
Retrieved on:
Thursday, December 15, 2022
The therapy has been available commercially to patients in France since September 2022.
Key Points:
- The therapy has been available commercially to patients in France since September 2022.
- KIMMTRAK’s approved indication, unresectable or metastatic uveal melanoma, is a rare and aggressive form of cancer affecting the eye.
- Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no specifically approved treatment prior to the approval of KIMMTRAK.
- Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
"Gadeta is excited to work with Immunocore on bringing these novel, soluble -TCRs to patients with solid tumors, said Marcel Zwaal, Chief Executive Officer of Gadeta.
Key Points:
- "Gadeta is excited to work with Immunocore on bringing these novel, soluble -TCRs to patients with solid tumors, said Marcel Zwaal, Chief Executive Officer of Gadeta.
- Gadeta is developing 201 TCR in its proprietary TEG (T Cells Engineered to Express a Defined Gamma Delta TCR) cell therapy platform as GDT201.
- Under the terms of the agreement, Immunocore and Gadeta will collaborate on 201 -TCR target discovery, and Immunocore will have the option to develop ImmTAC therapies derived from the 201 TCR as part of the research collaboration.
- Gadeta is discovering novel gamma delta () TCRs that enable the development of first-in-class cell therapies for the treatment of solid cancers.
Retrieved on:
Wednesday, November 9, 2022
During the third quarter of 2022, the Company continued to add new accounts prescribing KIMMTRAK in the United States, Germany, and France.
Key Points:
- During the third quarter of 2022, the Company continued to add new accounts prescribing KIMMTRAK in the United States, Germany, and France.
- The Company is on track to start the trial in the fourth quarter of 2022.
- SITC 2022 is being held November 8-12, 2022 in Boston Massachusetts.
- For the third quarter ended September 30, 2022, Immunocore reported net KIMMTRAK / tebentafusp revenues of 36.3 million (or $40.4 million).
